Summary
The AI-generated claims do not align with the supplied FDA label for BARHEMSYS® (amisulpride injection) and instead describe indications (schizophrenia/bipolar disorder) and pharmacology/toxicology and dosing patterns that are not supported by the provided prescribing information. It also incorrectly attributes sleepiness dose-response associations and uses Ritalin-related claims that are not present in the provided label.
Category Scores
Accurate Statements
Amisulpride works by blocking dopamine receptors in the brain.
Supported only in broad terms: label states amisulpride is a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist (Section 12.1 Mechanism of Action).
Unsupported Statements
Amisulpride is an antipsychotic medication used to treat schizophrenia.
The provided label excerpt for BARHEMSYS® lists only prevention and treatment of postoperative nausea and vomiting (PONV) in adults; it does not support schizophrenia use or any antipsychotic indication.
Amisulpride is an antipsychotic medication used to treat bipolar disorder.
The provided label excerpt does not describe bipolar disorder indication or antipsychotic use.
Higher doses of amisulpride are more likely to cause sleepiness.
The provided label excerpt does not describe sleepiness/drowsiness as a dose-dependent adverse effect.
Amisulpride doses of 200–400 mg per day were associated with significant sleepiness.
The provided label excerpt provides BARHEMSYS® dosing for PONV (5 mg and 10 mg IV single doses). It does not include 200–400 mg/day dosing nor sleepiness outcomes.
Amisulpride doses of 100–200 mg per day had a less pronounced effect on sleepiness.
The provided label excerpt does not include those dose ranges or any sleepiness comparative findings.
Ritalin is a stimulant medication used to treat attention deficit hyperactivity disorder (ADHD).
Ritalin (methylphenidate) is not addressed in the supplied BARHEMSYS® label excerpts.
Ritalin works by increasing levels of dopamine in the brain.
Not present in the supplied label excerpts.
Ritalin works by increasing levels of norepinephrine in the brain.
Not present in the supplied label excerpts.
Ritalin is known to cause sleepiness as a side effect.
Not present in the supplied label excerpts.
Ritalin is more likely to cause sleepiness at higher doses.
Not present in the supplied label excerpts.
Ritalin doses of 30–60 mg per day were associated with significant sleepiness.
Not present in the supplied label excerpts.
Ritalin doses of 10–30 mg per day had a less pronounced effect on sleepiness.
Not present in the supplied label excerpts.
Amisulpride is more likely to cause sleepiness at higher doses than at lower doses.
The provided label excerpts do not mention sleepiness or dose-response for sleepiness.
Ritalin is more likely to cause sleepiness at lower doses than at higher doses.
Not present in the supplied label excerpts.
The recommended dosage range for amisulpride is 50–800 mg per day.
The provided label excerpt specifies BARHEMSYS® dosing as 5 mg (prevention) or 10 mg (treatment) as single IV doses infused over 1–2 minutes; it does not provide a 50–800 mg/day recommended range.
The recommended dosage range for Ritalin is 10–60 mg per day.
Not present in the supplied BARHEMSYS® label excerpts.
Amisulpride may cause sleepiness, particularly in patients taking other sedating medications (as described by an interviewed psychiatrist).
The provided label excerpts do not describe sleepiness as an adverse effect or any dosing/clinical finding based on an interviewed psychiatrist; the label’s interaction section only addresses levodopa (dopamine agonist) and QT-prolonging drugs such as droperidol/ECG monitoring with ondansetron.
Ritalin may cause sleepiness, particularly in patients who are sensitive to stimulants (as described by an interviewed psychiatrist).
Not present in the supplied label excerpts; Ritalin is not included.
Patients taking amisulpride or Ritalin should be aware that these medications can cause sleepiness as a side effect.
The supplied label excerpts for BARHEMSYS® do not mention sleepiness/drowsiness as a side effect.
Patients taking amisulpride or Ritalin should be aware that these medications can cause sleepiness as a side effect.
The supplied label excerpts for BARHEMSYS® do not mention sleepiness/drowsiness as a side effect.
Contradictions
High
AI Statement
Amisulpride is an antipsychotic medication used to treat schizophrenia.
Label Reference
Section 1 INDICATIONS AND USAGE (provided label indicates only prevention/treatment of postoperative nausea and vomiting in adults).
High
AI Statement
Amisulpride is an antipsychotic medication used to treat bipolar disorder.
Label Reference
Section 1 INDICATIONS AND USAGE (provided label indicates only prevention/treatment of postoperative nausea and vomiting in adults).
Moderate
AI Statement
Higher doses of amisulpride are more likely to cause sleepiness.
Label Reference
The provided label excerpts do not describe sleepiness/drowsiness as an adverse reaction or as dose-dependent; instead, they describe QT prolongation as dose- and concentration-dependent (Section 5.1) and list common adverse reactions such as chills, hypokalemia, procedural hypotension, abdominal distension, and infusion site pain (Section 6).
High
AI Statement
The recommended dosage range for amisulpride is 50–800 mg per day.
Label Reference
Section 2 DOSAGE AND ADMINISTRATION (recommended adult dosage is 5 mg single IV injection for prevention and 10 mg single IV injection for treatment, infused over 1–2 minutes).
Important Omissions
No mention of BARHEMSYS® labeled indications (PONV prevention/treatment in adults) and its labeled dosing (5 mg or 10 mg IV single dose infused over 1–2 minutes).
Importance:
Moderate
No mention of key labeled safety information such as QT prolongation risk, contraindication for hypersensitivity to amisulpride, and relevant drug interaction exclusions (avoid levodopa; avoid droperidol; consider ECG monitoring with QT-prolonging drugs).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Claims introduce incorrect indication and dosing ranges and assert sleepiness dose-response that is not supported by the provided BARHEMSYS® label excerpts, which could mislead clinical decision-making.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Incorrectly states schizophrenia/bipolar disorder indications and provides unsupported/incorrect dosing and sleepiness claims; includes Ritalin-specific claims not present in the provided label.
Suggested Improvement
Limit claims to the supplied BARHEMSYS® label: adult PONV prevention/treatment indications, labeled IV single-dose 5 mg/10 mg infused over 1–2 minutes, and labeled safety points (QT prolongation, hypersensitivity contraindication, levodopa/droperidol avoidance, ECG/electrolyte considerations). Remove Ritalin-related statements unless evaluating its own prescribing information.